Skip to Content
MilliporeSigma
All Photos(1)

Key Documents

View All Documentation

74033AST

Supelco

Astec® CHIRALDEX™ G-PN Capillary GC Column

L × I.D. 30 m × 0.25 mm, df 0.12 μm

Synonym(s):

GC column, chiral, gamma-dextran

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

UNSPSC Code:
41115710
NACRES:
SB.54
Pricing and availability is not currently available.

material

fused silica

Quality Level

100

description

GC capillary column

packaging

1 ea of

parameter

-10-200 °C temperature (isothermal)
-10-220 °C temperature (programmed)

Beta value

500

df

0.12 μm

technique(s)

gas chromatography (GC): suitable

L × I.D.

30 m × 0.25 mm

matrix active group

non-bonded; 2,6-di-O-pentyl-3-propionyl derivative of γ-cyclodextrin phase

Looking for similar products? Visit Product Comparison Guide

Related Categories

Compare Similar Items

View Full Comparison

Show Differences

1 of 4

This Item
75033AST78023AST78033AST
Astec® CHIRALDEX™ G-PN Capillary GC Column L × I.D. 30 m × 0.25 mm, df 0.12 μm

74033AST

Astec® CHIRALDEX™ G-PN Capillary GC Column

Astec® CHIRALDEX™ G-BP Capillary GC Column L × I.D. 30 m × 0.25 mm, df 0.12 μm

75033AST

Astec® CHIRALDEX™ G-BP Capillary GC Column

Astec® CHIRALDEX™ B-DP Capillary GC Column L × I.D. 30 m × 0.25 mm, df 0.12 μm

78023AST

Astec® CHIRALDEX™ B-DP Capillary GC Column

Astec® CHIRALDEX™ G-DP Capillary GC Column L × I.D. 30 m × 0.25 mm, df 0.12 μm

78033AST

Astec® CHIRALDEX™ G-DP Capillary GC Column

df

0.12 μm

df

0.12 μm

df

0.12 μm

df

0.12 μm

matrix active group

non-bonded; 2,6-di-O-pentyl-3-propionyl derivative of γ-cyclodextrin phase

matrix active group

non-bonded; 2,6-di-O-pentyl-3-butyryl derivative of γ-cyclodextrin phase

matrix active group

non-bonded; 2,3-di-O-propionyl-6-t-butyl silyl derivative of β-cyclodextrin phase

matrix active group

non-bonded; 2,3-di-O-propionyl-6-t-butyl silyl derivative of γ-cyclodextrin phase

parameter

-10-200 °C temperature (isothermal), -10-220 °C temperature (programmed)

parameter

-10-200 °C temperature (isothermal), -10-220 °C temperature (programmed)

parameter

-10-200 °C temperature (isothermal), -10-220 °C temperature (programmed)

parameter

-10-200 °C temperature (isothermal), -10-220 °C temperature (programmed)

material

fused silica

material

fused silica

material

fused silica

material

fused silica

technique(s)

gas chromatography (GC): suitable

technique(s)

gas chromatography (GC): suitable

technique(s)

gas chromatography (GC): suitable

technique(s)

gas chromatography (GC): suitable

column type

capillary chiral

column type

capillary chiral

column type

capillary chiral

column type

capillary chiral

General description

Incorporates a phase consisting of a 2,6-di-O-pentyl-3-propionyl derivative of γ-cyclodextrin. This phase exhibits high selectivity for lactones and aromatic amines. It is also suitable for epoxide separations. Additionally, the analysis of styrene oxide can be accomplished on this phase (this analyte degrades on the TA phases).

Chem/Phys Resistance

Temp. Limits:
  • -10 °C to 200 °C isothermal, 220 °C programmed

Other Notes

We offer a variety of chromatography accessories including analytical syringes

Legal Information

Astec is a registered trademark of Merck KGaA, Darmstadt, Germany
CHIRALDEX is a trademark of Sigma-Aldrich Co. LLC
  • Specification Sheet

    • Choose from one of the most recent versions:

    Certificates of Analysis (COA)

    Lot/Batch Number
    281671-04
    281671-03
    281671-02
    281671-01
    278324-04

    Don't see the Right Version?

    If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

    Search for a COA

    Already Own This Product?

    Find documentation for the products that you have recently purchased in the Document Library.

    Visit the Document Library

    Virginia A Moyer
    Annals of internal medicine, 159(10), 698-708 (2013-09-26)
    Update of the 2002 U.S. Preventive Services Task Force (USPSTF) recommendation on the use of medications for breast cancer risk reduction. The USPSTF reviewed evidence on the effectiveness,adverse effects, and subgroup variations of medications to reduce the risk for breast
    Yuko Nishi et al.
    Kidney international, 83(4), 662-673 (2013-01-25)
    Proteinuria is an independent risk factor for progressive renal diseases because it initiates or aggravates tubulointerstitial injury. Clinically, females are less susceptible to progression of chronic kidney disease; however, the mechanisms underlying the renoprotective effect of estrogen receptor stimulation have
    Tuan Hiep Tran et al.
    International journal of pharmaceutics, 443(1-2), 50-57 (2013-01-16)
    The aim of this study was to improve the physicochemical properties and bioavailability of a poorly water-soluble drug, raloxifene by solid dispersion (SD) nanoparticles using the spray-drying technique. These spray-dried SD nanoparticles were prepared with raloxifene (RXF), polyvinylpyrrolidone (PVP) and
    Daniel J Schaid et al.
    Genetic epidemiology, 37(3), 229-238 (2013-01-26)
    Genome-wide association studies (GWAS) of complex traits have generated many association signals for single nucleotide polymorphisms (SNPs). To understand the underlying causal genetic variant(s), focused DNA resequencing of targeted genomic regions is commonly used, yet the current cost of resequencing
    Aysegul Kavas et al.
    Journal of biosciences, 38(1), 135-147 (2013-02-07)
    The aim of this study was to investigate the effects of Raloxifene (Ral) on degeneration-related changes in osteoarthritis (OA)-like chondrocytes using two- and three-dimensional models. Five-azacytidine (Aza-C) was used to induce OA-like alterations in rat articular chondrocytes and the model
    View All Related Papers

    Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

    Contact Technical Service